ea0026p584 | Clinical case reports | ECE2011
Dandamudi Ravi
, Hocking M
Introduction: Tolvaptan is an oral vasopressin V2 receptor antagonist which offers a targeted approach in regulating body water and serum [Na+] and is a novel treatment for hyponatraemia secondary to SIADH. Here we report our first case experience with tolvaptan comparing its efficacy with conventional treatments in the same patient.Case report: A 52-year-old lady was admitted with confusion, nausea and vomiting. She gave a 3-month ...